Can non-HLA single nucleotide polymorphisms help stratify risk in TrialNet relatives at risk for type 1 diabetes?

Andrea K. Steck, Ping Xu, Susan Geyer, Maria J. Redondo, Peter Antinozzi, John M. Wentworth, Jay Sosenko, Suna Onengut-Gumuscu, Wei Min Chen, Stephen Rich, Alberto Pugliese, Type 1 Diabetes TrialNet Study Group

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)

Abstract

Context: Genome-wide association studies identified >50 type 1 diabetes (T1D) associated nonhuman leukocyte antigens (non-HLA) loci. Objective: The purpose of this study was to assess the contribution of non-HLA single nucleotide polymorphisms (SNPs) to risk of disease progression. Design and Setting: The TrialNet Pathway to Prevention Study follows relatives of T1D patients for development of autoantibodies (Abs) and T1D. Participants: Using the Immunochip, we analyzed 53 diabetes-associated, non-HLA SNPs in 1016 Abpositive, at-risk non-Hispanic white relatives. Main Outcome Measure: Effect of SNPs on the development of multiple Abs and T1D. Results: Cox proportional analyses included all substantial non-HLA SNPs, HLA genotypes, relationship to proband, sex, age at initial screening, initial Ab type, and number. Factors involved in progression from single to multiple Abs included age at screening, relationship to proband, HLA genotypes, and rs3087243 (cytotoxic T lymphocyte antigen-4). Significant factors for diabetes progression included age at screening, Ab number, HLA genotypes, rs6476839 [GLIS family zinc finger 3 (GLIS3)], and rs3184504 [SH2B adaptor protein 3 (SH2B3)]. When glucose area under the curve (AUC) was included, factors involved in disease progression included glucose AUC, age at screening, Ab number, relationship to proband, HLA genotypes, rs6476839 (GLIS3), and rs7221109 (CCR7). In stratified analyses by age, glucose AUC, age at screening, sibling, HLA genotypes, rs6476839 (GLIS3), and rs4900384 (C14orf64) were significantly associated with progression to diabetes in participants <12 years old, whereas glucose AUC, sibling, rs3184504 (SH2B3), and rs4900384 (C14orf64) were significant in those ≥12. Conclusions: In conclusion, we identified five non-HLA SNPs associated with increased risk of progression from Ab positivity to disease that may improve risk stratification for prevention trials.

Original languageEnglish
Pages (from-to)2873-2880
Number of pages8
JournalJournal of Clinical Endocrinology and Metablism
Volume102
Issue number8
DOIs
Publication statusPublished - 1 Aug 2017
Externally publishedYes

Cite this

Steck, A. K., Xu, P., Geyer, S., Redondo, M. J., Antinozzi, P., Wentworth, J. M., ... Type 1 Diabetes TrialNet Study Group (2017). Can non-HLA single nucleotide polymorphisms help stratify risk in TrialNet relatives at risk for type 1 diabetes? Journal of Clinical Endocrinology and Metablism, 102(8), 2873-2880. https://doi.org/10.1210/jc.2016-4003
Steck, Andrea K. ; Xu, Ping ; Geyer, Susan ; Redondo, Maria J. ; Antinozzi, Peter ; Wentworth, John M. ; Sosenko, Jay ; Onengut-Gumuscu, Suna ; Chen, Wei Min ; Rich, Stephen ; Pugliese, Alberto ; Type 1 Diabetes TrialNet Study Group. / Can non-HLA single nucleotide polymorphisms help stratify risk in TrialNet relatives at risk for type 1 diabetes?. In: Journal of Clinical Endocrinology and Metablism. 2017 ; Vol. 102, No. 8. pp. 2873-2880.
@article{b5728ab208384ddd8f6a5faec8b50e22,
title = "Can non-HLA single nucleotide polymorphisms help stratify risk in TrialNet relatives at risk for type 1 diabetes?",
abstract = "Context: Genome-wide association studies identified >50 type 1 diabetes (T1D) associated nonhuman leukocyte antigens (non-HLA) loci. Objective: The purpose of this study was to assess the contribution of non-HLA single nucleotide polymorphisms (SNPs) to risk of disease progression. Design and Setting: The TrialNet Pathway to Prevention Study follows relatives of T1D patients for development of autoantibodies (Abs) and T1D. Participants: Using the Immunochip, we analyzed 53 diabetes-associated, non-HLA SNPs in 1016 Abpositive, at-risk non-Hispanic white relatives. Main Outcome Measure: Effect of SNPs on the development of multiple Abs and T1D. Results: Cox proportional analyses included all substantial non-HLA SNPs, HLA genotypes, relationship to proband, sex, age at initial screening, initial Ab type, and number. Factors involved in progression from single to multiple Abs included age at screening, relationship to proband, HLA genotypes, and rs3087243 (cytotoxic T lymphocyte antigen-4). Significant factors for diabetes progression included age at screening, Ab number, HLA genotypes, rs6476839 [GLIS family zinc finger 3 (GLIS3)], and rs3184504 [SH2B adaptor protein 3 (SH2B3)]. When glucose area under the curve (AUC) was included, factors involved in disease progression included glucose AUC, age at screening, Ab number, relationship to proband, HLA genotypes, rs6476839 (GLIS3), and rs7221109 (CCR7). In stratified analyses by age, glucose AUC, age at screening, sibling, HLA genotypes, rs6476839 (GLIS3), and rs4900384 (C14orf64) were significantly associated with progression to diabetes in participants <12 years old, whereas glucose AUC, sibling, rs3184504 (SH2B3), and rs4900384 (C14orf64) were significant in those ≥12. Conclusions: In conclusion, we identified five non-HLA SNPs associated with increased risk of progression from Ab positivity to disease that may improve risk stratification for prevention trials.",
author = "Steck, {Andrea K.} and Ping Xu and Susan Geyer and Redondo, {Maria J.} and Peter Antinozzi and Wentworth, {John M.} and Jay Sosenko and Suna Onengut-Gumuscu and Chen, {Wei Min} and Stephen Rich and Alberto Pugliese and {Type 1 Diabetes TrialNet Study Group}",
year = "2017",
month = "8",
day = "1",
doi = "10.1210/jc.2016-4003",
language = "English",
volume = "102",
pages = "2873--2880",
journal = "Journal of Clinical Endocrinology and Metablism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "8",

}

Steck, AK, Xu, P, Geyer, S, Redondo, MJ, Antinozzi, P, Wentworth, JM, Sosenko, J, Onengut-Gumuscu, S, Chen, WM, Rich, S, Pugliese, A & Type 1 Diabetes TrialNet Study Group 2017, 'Can non-HLA single nucleotide polymorphisms help stratify risk in TrialNet relatives at risk for type 1 diabetes?', Journal of Clinical Endocrinology and Metablism, vol. 102, no. 8, pp. 2873-2880. https://doi.org/10.1210/jc.2016-4003

Can non-HLA single nucleotide polymorphisms help stratify risk in TrialNet relatives at risk for type 1 diabetes? / Steck, Andrea K.; Xu, Ping; Geyer, Susan; Redondo, Maria J.; Antinozzi, Peter; Wentworth, John M.; Sosenko, Jay; Onengut-Gumuscu, Suna; Chen, Wei Min; Rich, Stephen; Pugliese, Alberto; Type 1 Diabetes TrialNet Study Group.

In: Journal of Clinical Endocrinology and Metablism, Vol. 102, No. 8, 01.08.2017, p. 2873-2880.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Can non-HLA single nucleotide polymorphisms help stratify risk in TrialNet relatives at risk for type 1 diabetes?

AU - Steck, Andrea K.

AU - Xu, Ping

AU - Geyer, Susan

AU - Redondo, Maria J.

AU - Antinozzi, Peter

AU - Wentworth, John M.

AU - Sosenko, Jay

AU - Onengut-Gumuscu, Suna

AU - Chen, Wei Min

AU - Rich, Stephen

AU - Pugliese, Alberto

AU - Type 1 Diabetes TrialNet Study Group

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Context: Genome-wide association studies identified >50 type 1 diabetes (T1D) associated nonhuman leukocyte antigens (non-HLA) loci. Objective: The purpose of this study was to assess the contribution of non-HLA single nucleotide polymorphisms (SNPs) to risk of disease progression. Design and Setting: The TrialNet Pathway to Prevention Study follows relatives of T1D patients for development of autoantibodies (Abs) and T1D. Participants: Using the Immunochip, we analyzed 53 diabetes-associated, non-HLA SNPs in 1016 Abpositive, at-risk non-Hispanic white relatives. Main Outcome Measure: Effect of SNPs on the development of multiple Abs and T1D. Results: Cox proportional analyses included all substantial non-HLA SNPs, HLA genotypes, relationship to proband, sex, age at initial screening, initial Ab type, and number. Factors involved in progression from single to multiple Abs included age at screening, relationship to proband, HLA genotypes, and rs3087243 (cytotoxic T lymphocyte antigen-4). Significant factors for diabetes progression included age at screening, Ab number, HLA genotypes, rs6476839 [GLIS family zinc finger 3 (GLIS3)], and rs3184504 [SH2B adaptor protein 3 (SH2B3)]. When glucose area under the curve (AUC) was included, factors involved in disease progression included glucose AUC, age at screening, Ab number, relationship to proband, HLA genotypes, rs6476839 (GLIS3), and rs7221109 (CCR7). In stratified analyses by age, glucose AUC, age at screening, sibling, HLA genotypes, rs6476839 (GLIS3), and rs4900384 (C14orf64) were significantly associated with progression to diabetes in participants <12 years old, whereas glucose AUC, sibling, rs3184504 (SH2B3), and rs4900384 (C14orf64) were significant in those ≥12. Conclusions: In conclusion, we identified five non-HLA SNPs associated with increased risk of progression from Ab positivity to disease that may improve risk stratification for prevention trials.

AB - Context: Genome-wide association studies identified >50 type 1 diabetes (T1D) associated nonhuman leukocyte antigens (non-HLA) loci. Objective: The purpose of this study was to assess the contribution of non-HLA single nucleotide polymorphisms (SNPs) to risk of disease progression. Design and Setting: The TrialNet Pathway to Prevention Study follows relatives of T1D patients for development of autoantibodies (Abs) and T1D. Participants: Using the Immunochip, we analyzed 53 diabetes-associated, non-HLA SNPs in 1016 Abpositive, at-risk non-Hispanic white relatives. Main Outcome Measure: Effect of SNPs on the development of multiple Abs and T1D. Results: Cox proportional analyses included all substantial non-HLA SNPs, HLA genotypes, relationship to proband, sex, age at initial screening, initial Ab type, and number. Factors involved in progression from single to multiple Abs included age at screening, relationship to proband, HLA genotypes, and rs3087243 (cytotoxic T lymphocyte antigen-4). Significant factors for diabetes progression included age at screening, Ab number, HLA genotypes, rs6476839 [GLIS family zinc finger 3 (GLIS3)], and rs3184504 [SH2B adaptor protein 3 (SH2B3)]. When glucose area under the curve (AUC) was included, factors involved in disease progression included glucose AUC, age at screening, Ab number, relationship to proband, HLA genotypes, rs6476839 (GLIS3), and rs7221109 (CCR7). In stratified analyses by age, glucose AUC, age at screening, sibling, HLA genotypes, rs6476839 (GLIS3), and rs4900384 (C14orf64) were significantly associated with progression to diabetes in participants <12 years old, whereas glucose AUC, sibling, rs3184504 (SH2B3), and rs4900384 (C14orf64) were significant in those ≥12. Conclusions: In conclusion, we identified five non-HLA SNPs associated with increased risk of progression from Ab positivity to disease that may improve risk stratification for prevention trials.

UR - http://www.scopus.com/inward/record.url?scp=85026907403&partnerID=8YFLogxK

U2 - 10.1210/jc.2016-4003

DO - 10.1210/jc.2016-4003

M3 - Article

VL - 102

SP - 2873

EP - 2880

JO - Journal of Clinical Endocrinology and Metablism

JF - Journal of Clinical Endocrinology and Metablism

SN - 0021-972X

IS - 8

ER -